4-(BENZO[C][1,2,5]OXADIAZOL-5-YLMETHOXY)-3-METHYLBENZOFURAN-2-CARBOXYLIC ACID


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	CMIBWCCRWSUGLJ-UHFFFAOYSA-N
Smiles	Cc1c(oc2cccc(OCc3ccc4nonc4c3)c12)C(=O)O
InChI	InChI=1S/C17H12N2O5/c1-9-15-13(3-2-4-14(15)23-16(9)17(20)21)22-8-10-5-6-11-12(7-10)19-24-18-11/h2-7H,8H2,1H3,(H,20,21)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C17H12N2O5
Molecular Weight	324.29
AlogP	3.68
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	98.59
Molecular species	ACID
Aromatic Rings	4.0
Heavy Atoms	24.0

Assay Description	Organism	Bioactivity
Selectivity Rattus norvegicus (rat)io of IC50 for ETB receptor in Sprague-Dawley Rattus norvegicus (rat) myocardium to IC50 for ETA receptor in Sprague-Dawley Rattus norvegicus (rat) myocardium	Rattus norvegicus	27.0
Displacement of [125I]ET-1 from ETB receptor in Sprague-Dawley Rattus norvegicus (rat) myocardium after 1 hr	Rattus norvegicus	1070.0 nM
Displacement of [125I]ET-1 from ETA receptor in Sprague-Dawley Rattus norvegicus (rat) myocardium after 1 hr	Rattus norvegicus	39.0 nM
Antagonist activity at ETA receptor in Sprague-Dawley Rattus norvegicus (rat) thoracic aortic ring assessed as inhibition of ET1-induced thoracic aortic ring contraction at 10 uM after 30 min relative to control	Rattus norvegicus	70.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2296900
PubChem	76320429

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).